SVB Leerink Analysts Boost Earnings Estimates for Viracta Therapeutics, Inc. (NASDAQ:VIRX)

Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) – Investment analysts at SVB Leerink upped their Q1 2023 earnings per share estimates for shares of Viracta Therapeutics in a research report issued to clients and investors on Tuesday, March 14th. SVB Leerink analyst A. Berens now expects that the company will post earnings of ($0.32) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($1.20) per share. SVB Leerink also issued estimates for Viracta Therapeutics’ Q2 2023 earnings at ($0.27) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.27) EPS, FY2023 earnings at ($1.12) EPS, FY2024 earnings at ($1.36) EPS, FY2025 earnings at ($0.62) EPS and FY2026 earnings at ($0.68) EPS.

Several other analysts have also recently commented on VIRX. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Viracta Therapeutics in a research report on Tuesday, March 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Viracta Therapeutics in a research report on Tuesday, March 14th.

Viracta Therapeutics Stock Performance

Shares of NASDAQ VIRX opened at $1.65 on Friday. The company has a quick ratio of 8.49, a current ratio of 9.36 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $63.38 million, a price-to-earnings ratio of -1.27 and a beta of 1.33. The stock’s fifty day simple moving average is $1.91 and its 200 day simple moving average is $2.80. Viracta Therapeutics has a 52-week low of $1.21 and a 52-week high of $5.75.

Institutional Trading of Viracta Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Ensign Peak Advisors Inc boosted its position in Viracta Therapeutics by 4.8% during the second quarter. Ensign Peak Advisors Inc now owns 63,406 shares of the company’s stock valued at $246,000 after purchasing an additional 2,891 shares during the last quarter. Geode Capital Management LLC boosted its position in Viracta Therapeutics by 3.0% during the fourth quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock valued at $327,000 after purchasing an additional 6,502 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Viracta Therapeutics by 65.5% during the third quarter. Cubist Systematic Strategies LLC now owns 22,371 shares of the company’s stock valued at $96,000 after purchasing an additional 8,854 shares during the last quarter. State Street Corp boosted its position in Viracta Therapeutics by 2.3% during the first quarter. State Street Corp now owns 588,603 shares of the company’s stock valued at $2,802,000 after purchasing an additional 13,514 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Viracta Therapeutics during the fourth quarter valued at $29,000. Institutional investors and hedge funds own 32.35% of the company’s stock.

About Viracta Therapeutics

(Get Rating)

Viracta Therapeutics, Inc a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.